WA
PTLA

WealthTrust Axiom’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

WealthTrust Axiom’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,000
Closed -$208K – 245
2019
Q1 		$208K Buy
+6,000
New +$173K 0.07% 196

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

WealthTrust Axiom's PTLA Position: Q2 2019 in Review

WealthTrust Axiom sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2019, closing a stake of 6,000 shares — an estimated $208K sold.

WealthTrust Axiom first reported a position in PTLA in Q1 2019 and held it in 1 quarter. The position peaked at $208K in Q1 2019. 201 funds tracked by Wall St. Rank hold PTLA as of Q2 2019.

  • WealthTrust Axiom reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • WealthTrust Axiom sold 6,000 Portola Pharmaceuticals, Inc. shares in Q2 2019, an estimated $208K.
  • WealthTrust Axiom first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • WealthTrust Axiom's Portola Pharmaceuticals, Inc. position peaked at $208K in Q1 2019.
  • 201 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2019.

Based on WealthTrust Axiom's 13F filing for Q2 2019, filed 7 Aug 2019.